A important advancement in blood sugar treatment is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 receptor, and https://travialist.com/story11699599/revolutionary-development-tirzepatide-45mg-for-glucose-control